Image via Wikipedia
Company announced a manufacturer of drugs that they had tested a new drug intended for patients with chronic myelogenous leukemia, a type of chronic leukemia, and results were positive in 47% of those taking the treatment.
Bloomberg quoted U.S. network for scientists who led the research team at a meeting of the American Society for Blood Research, the patients who experience the respondents were suffering from the type that does not treat his leukemia, or did not respond by the drug.
The director of the company Eraad manufacturer of the drug's new Harvey Berger, "It is a disease whose cure is very difficult because the patients become resistant to treatment," he added, "even in patients who are in advanced stages of the disease, we are witnessing what may be considered by most doctors reaction to important and useful clinically."
Included the experience - the second of three trials were conducted in order to obtain approval from the competent authorities of the U.S. Drug - 449 patients each suffering from a boom called "T315I", which did not authorize any drugs after her.
It was found that nearly 65% of patients who suffer from this genetic mutation showed a cell in response to medication, an objective test, which means that it is to have a smaller number of abnormal cells associated with the disease after taking the drug.
The company said the new drug manufacturer would submit it for approval by mid-2012, next in the light of the results of experiments, noting that it will seek to help develop the treatment by selling some of its international rights.
Source: UPI